Platelet receptors as therapeutic targets: Past, present and future

被引：62

作者：

Jamasbi, Janina ^{[1
]}

Ayabe, Keng ^{[2
]}

Goto, Shinya ^{[2
]}

Nieswandt, Bernhard ^{[3
,4
]}

Peter, Karlheinz ^{[5
]}

Siess, Wolfgang ^{[1
,6
]}

机构：

[1] Ludwig Maximilians Univ Munchen, Inst Prevent Cardiovasc Dis, Munich, Germany

[2] Tokai Univ, Sch Med, Dept Med Cardiol, Isehara, Kanagawa, Japan

[3] Univ Wurzburg, Univ Hosp, Expt Biomed, Wurzburg, Germany

[4] Univ Wurzburg, Rudolf Virchow Ctr, Wurzburg, Germany

[5] Baker IDI Heart & Diabet Inst, Atherothrombosis & Vasc Biol, Melbourne, Vic, Australia

[6] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany

来源：

THROMBOSIS AND HAEMOSTASIS | 2017年 / 117卷 / 07期

基金：

英国医学研究理事会;

关键词：

Antiplatelet agents; GP Ib alpha; GP VI; GP IIb/IIIa; PAR-1; VON-WILLEBRAND-FACTOR; ACUTE CORONARY SYNDROMES; INDUCED THROMBUS FORMATION; INTIMA-MEDIA THICKNESS; GLYCOPROTEIN IB-ALPHA; ANTI-GPVI ANTIBODIES; CONTROLLED PHASE-II; IN-VIVO; ANTIPLATELET THERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1160/TH16-12-0911

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ib alpha, and directed against GPVI, GPIIb/IIIa (integrin alpha(IIb)beta(3)), the thrombin receptor PAR-1, and the ADP receptor P2Y(12). The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.

引用

页码：1249 / 1257

页数：9

共 50 条

[31] Chemokine receptors - Future therapeutic targets for HIV!
Proudfoot, AEI
Wells, TNC
Clapham, PR
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (05) : 451 - 463
[32] Targeting chemokine receptors for HIV: past, present and future
Fricker, Simon P.
FUTURE MEDICINAL CHEMISTRY, 2015, 7 (17) : 2311 - 2315
[33] Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, and Future
Funder, John W.
ENDOCRINOLOGY, 2010, 151 (11) : 5098 - 5102
[34] 5-HT RECEPTORS - PAST, PRESENT AND FUTURE
PEROUTKA, SJ
TRENDS IN NEUROSCIENCES, 1995, 18 (02) : 68 - 69
[35] Therapeutic manipulation of the microbiota: past, present, and considerations for the future
Young, V. B.
CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (11) : 905 - 909
[36] Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
Weber, Christian
Badimon, Lina
Mach, Francois
van der Vorst, Emiel P. C.
THROMBOSIS AND HAEMOSTASIS, 2017, 117 (07) : 1258 - 1264
[37] The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Robin L Carhart-Harris
Guy M Goodwin
Neuropsychopharmacology, 2017, 42 : 2105 - 2113
[38] Therapeutic management of hereditary angioedema: past, present, and future
Valerieva, Anna
Nedeva, Denislava
Yordanova, Vania
Petkova, Elena
Staevska, Maria
BALKAN MEDICAL JOURNAL, 2021, 38 (02) : 89 - 103
[39] The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, Robin L.
Goodwin, Guy M.
NEUROPSYCHOPHARMACOLOGY, 2017, 42 (11) : 2105 - 2113
[40] THERAPEUTIC UPPER GASTROINTESTINAL ENDOSCOPY - PAST, PRESENT, AND FUTURE
LAMBERT, R
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1990, 25 : 63 - 76

← 1 2 3 4 5 →